Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2834200 | 0.90 | EIF2S1 (0.38) | AKR1C3AKR1C2S1PR3SCN9AAAK1 | |
| SCHEMBL2834950 | 0.87 | S1PR3 (0.40) | S1PR3AAK1DYRK1A | |
| SCHEMBL2839734 | 0.86 | S1PR3 (0.36) | AKR1C3AKR1C2S1PR3SCN9AAAK1 | |
| SCHEMBL2836835 | 0.84 | S1PR3 (0.41) | AKR1C3AKR1C2S1PR3SCN9AKCNH2 | |
| SCHEMBL2838698 | 0.80 | CYP3A4 (0.36) | S1PR3AAK1DYRK1A | |
| SCHEMBL7803598 | 0.79 | AKR1C3 (0.44) | AKR1C3AKR1C2SCN9AAAK1KCNH2 | |
| SCHEMBL2839096 | 0.76 | S1PR3 (0.42) | AKR1C3AKR1C2S1PR3AAK1ROCK2 | |
| SCHEMBL2841558 | 0.76 | S1PR3 (0.38) | S1PR3AAK1GRIN2BDYRK1A | |
| SCHEMBL2833338 | 0.75 | S1PR3 (0.42) | AKR1C3AKR1C2S1PR3AAK1ROCK2 | |
| SCHEMBL2833981 | 0.75 | CYP3A4 (0.40) | AKR1C3AKR1C2S1PR3AAK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367838-B2 | Amines or amino alcohols as GLYT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | KOLCZEWSKI SABINE (DE) | 2012-09-13 | — | — | US | disclosed |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232033-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | AKR1C3 1313/4885AKR1C2 924/4885S1PR3 2311/4885 |
| US-20100210592-A1 | AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS | GFPT1, CEPT1, SLC18A2 | AKR1C3 1313/4885AKR1C2 924/4885S1PR3 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.